[177镥-PSMA-617治疗、剂量测定及转移性去势抵抗性前列腺癌患者的随访]
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
作者信息
Fendler Wolfgang P, Kratochwil Clemens, Ahmadzadehfar Hojjat, Rahbar Kambiz, Baum Richard P, Schmidt Matthias, Pfestroff Andreas, Lützen Ulf, Prasad Vikas, Heinzel Alexander, Heuschkel Martin, Ruf Juri, Bartenstein Peter, Krause Bernd J
机构信息
Prof. Dr. Bernd Joachim Krause, Deutsche Gesellschaft für Nuklearmedizin e. V., Nikolaistr. 29, 37073 Göttingen,
出版信息
Nuklearmedizin. 2016 Jun 28;55(3):123-8.
Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize 177Lu-PSMA-617 RLT, and improve quality of individual patient care.
对于转移性去势抵抗性前列腺癌（mCRPC）患者，在其他治疗方案均已用尽后，可采用使用177Lu标记的前列腺特异性膜抗原抑制剂（177Lu-PSMA）进行放射性配体疗法（RLT）。自2013年起，德国大学诊所基于同情用药原则提供RLT。本共识文件包含了关于使用177Lu-PSMA-617进行RLT的建议。这些共识声明由德国核医学协会（DGN）于2015年12月组建的一个专家小组制定。声明包括关于适应症、基线检查、治疗方案、联合治疗、剂量测定和随访的建议。共识建议旨在为医护人员提供信息，规范177Lu-PSMA-617 RLT，并提高个体患者护理质量。
Zotero 插件